Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.55
Bid: 3.50
Ask: 3.60
Change: -0.30 (-7.79%)
Spread: 0.10 (2.857%)
Open: 3.85
High: 3.85
Low: 3.55
Prev. Close: 3.85
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM and Appointment of Joint Broker

30 Jun 2022 15:00

RNS Number : 8793Q
ValiRx PLC
30 June 2022
 

30 June 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Result of AGM and Appointment of Joint Broker

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. Details of the votes received will be available shortly on the Company's website.

As announced on 7 June 2022, Kevin Alexander has ceased to be a director of the Company following the conclusion of the AGM.

Appointment of Joint Broker

Further to the announcement made today in relation to the Company's fundraise, the Company is pleased to announce the appointment of Turner Pope Investments (TPI) Limited as joint broker to the Company with immediate effect.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

 

Dr Suzanne Dilly, CEO

 

Tel: +44 (0) 2476 796496

www.valirx.com

Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser)

 

Liam Murray/Jo Turner/Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 088

Cenkos Securities Limited (Joint Broker)

 

Russell Kerr/Michael Johnson (Sales)

 

Callum Davidson/Giles Balleny (Corporate Finance)

Tel: +44 (0) 20 7397 8900

Turner Pope Investments (TPI) Limited (Joint Broker)

 

James Pope / Andy Thacker  

Tel: +44 (0) 20 3657 0050

 

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCXBLFXLQLEBBZ
Date   Source Headline
21st Mar 20247:00 amRNSEvaluation Agreement with Imperial College London
19th Mar 20247:00 amRNSBoard Re-structuring and update on requisition
4th Mar 20245:47 pmRNSShareholder Requisition Notice
4th Mar 20247:00 amRNSProposed Appointment of Non-Executive Director
29th Feb 20242:00 pmRNSProposed Appointment of Non-Executive Director
13th Feb 20242:20 pmRNSFurther re Shareholder Requisition Notice
9th Feb 20245:06 pmRNSShareholder Requisition Notice
19th Jan 20247:00 amRNSChange of Broker
18th Jan 20247:00 amRNSDirectorate Change
4th Jan 20241:48 pmRNSResult of GM, Issue of Equity
19th Dec 20236:11 pmRNSResult of Retail Offer, Subscription
15th Dec 20237:00 amRNSPosting of Circular, Notice of GM and Ops Review
13th Dec 20234:56 pmRNSRetail Offer
13th Dec 20234:49 pmRNSConditional Fundraise, Notice of General Meeting
5th Dec 20237:00 amRNSAgreement to License VAL401 to Ambrose Healthcare
10th Nov 20237:00 amRNSEvaluation Agreement with StingRay Bio
6th Oct 202310:45 amRNSStatement re Share Price Movement
28th Sep 20237:00 amRNSOperational Review
24th Aug 20237:00 amRNSHalf-year Report
14th Aug 20237:00 amRNSCollaborative Services Agreement
19th Jul 20237:00 amRNSInaphaea BioLabs secures first external contract
28th Jun 20232:15 pmRNSResult of AGM
20th Jun 20237:00 amRNSVirtual AGM Access
19th Jun 20237:00 amRNSInaphaea BioLabs Operational Update
16th Jun 20237:00 amRNSConclusion of Hokkaido Evaluation Agreement
14th Jun 20237:00 amRNSAsset Purchase – Imagen Therapeutics
8th Jun 20237:00 amRNSUpdate on proposed sub-license of VAL201
7th Jun 20237:00 amRNSExpanded agreement with University of Barcelona
5th Jun 20237:00 amRNSFinal Results and Notice of AGM
26th May 20237:00 amRNSNotice of Results and Investor Webinar
26th Apr 20237:00 amRNSCollaborative Services Agreement
31st Mar 20237:00 amRNSQuarterly Operational Update
1st Mar 20237:02 amRNSInvestor Webinar
1st Mar 20237:00 amRNSIncorporation of Inaphaea BioLabs Limited
24th Feb 20234:40 pmRNSSecond Price Monitoring Extn
24th Feb 20234:35 pmRNSPrice Monitoring Extension
2nd Feb 202312:45 pmRNSResult of GM, Issue of Equity
31st Jan 20237:02 amRNSOperational Update
31st Jan 20237:00 amRNSHolding(s) in Company
17th Jan 20234:36 pmRNSBroker Offer Results
17th Jan 20239:22 amRNSPosting of Circular and Notice of General Meeting
13th Jan 20237:01 amRNSLaunch of Broker Offer
13th Jan 20237:00 amRNSIssue of Equity & Proposed Broker Offer
14th Dec 20225:01 pmRNSHolding(s) in Company
7th Dec 20221:06 pmRNSHolding(s) in Company
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
6th Dec 202212:00 pmRNSShareholder Communications and Investor Webinar
6th Dec 20227:00 amRNSQuarterly Operational and Strategy Update
24th Oct 20227:00 amRNSSubsidiary Launched and IP License Signed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.